{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:49:30Z","timestamp":1787755770377,"version":"build-2784847793"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","award":["U114000"],"award-info":[{"award-number":["U114000"]}],"id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-zai2022\/zd-0088"],"award-info":[{"award-number":["Y-zai2022\/zd-0088"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-Gilead2024-ZD-0082"],"award-info":[{"award-number":["Y-Gilead2024-ZD-0082"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ygyno.2025.06.023","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T18:15:43Z","timestamp":1751652943000},"page":"124-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Low-dose lenvatinib plus toripalimab for patients with platinum-resistant recurrent ovarian cancer: preliminary results from a multicenter, phase II trial (NCT06241105)"],"prefix":"10.1016","volume":"199","author":[{"given":"Hao","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongruo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingle","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengzhi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2025.06.023_bb0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl. 6","key":"10.1016\/j.ygyno.2025.06.023_bb0010","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol. 2018 Oct 1;29(Suppl 4):iv259. doi:10.1093\/annonc\/mdy157.]","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2025.06.023_bb0015","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial [published correction appears in J Clin Oncol. 2014 Dec 10;32(35):4025]","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.023_bb0020","article-title":"Niraparib, dostarlimab, and bevacizumab as combination therapy in pretreated, advanced platinum-resistant ovarian cancer: findings from cohort a of the OPAL phase II trial","volume":"8","author":"Liu","year":"2024","journal-title":"JCO Precis. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2025.06.023_bb0025","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ygyno.2025.06.023_bb0030","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol."},{"issue":"10126","key":"10.1016\/j.ygyno.2025.06.023_bb0035","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"16_suppl","key":"10.1016\/j.ygyno.2025.06.023_bb0040","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1200\/JCO.2024.42.16_suppl.5581","article-title":"Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer","volume":"42","author":"Bauer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.023_bb0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2024.04.011","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: results from the phase 2 multicohort LEAP-005 study","volume":"186","author":"Gonz\u00e1lez-Mart\u00edn","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.06.023_bb0050","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ygyno.2025.06.023_bb0055","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/cen.15214","article-title":"Low-dose versus high-dose lenvatinib in radioiodine refractory differentiated thyroid cancer-a real-world safety and efficacy analysis","volume":"102","author":"Moulika","year":"2025","journal-title":"Clin. Endocrinol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.06.023_bb0060","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2021.04.034","article-title":"Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer","volume":"162","author":"How","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2025.06.023_bb0065","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1136\/ijgc-2024-005331","article-title":"Low-dose lenvatinib and anti-programmed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer: a pilot study","volume":"34","author":"Shang","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.06.023_bb0070","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2147\/IJWH.S502665","article-title":"Efficacy and safety of low-dose lenvatinib and toripalimab in patients with recurrent platinum-resistant ovarian cancer: study protocol of a multicenter, open-label, single-arm, phase II clinical trial","volume":"17","author":"Su","year":"2025","journal-title":"Int. J. Women\u2019s Health"},{"issue":"2","key":"10.1016\/j.ygyno.2025.06.023_bb0075","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","article-title":"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study","volume":"35","author":"Yan","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.06.023_bb0080","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.ygyno.2025.06.023_bb0085","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00262-024-03841-z","article-title":"Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study","volume":"73","author":"Wang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.ygyno.2025.06.023_bb0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological Cancer intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.06.023_bb0095","first-page":"A64","article-title":"297 Leap-005: evaluating the safety and efficacy of lenvatinib and pembrolizumab in patients previously treated for ovarian cancer, a multi-cohort phase 2 study","volume":"30","author":"Gonzalez-Martin","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"23","key":"10.1016\/j.ygyno.2025.06.023_bb0100","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2025.06.023_bb0105","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.023_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107281","article-title":"Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: a systematic review","volume":"91","author":"Mo","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ygyno.2025.06.023_bb0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.10.002","article-title":"Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer","volume":"106","author":"Tahara","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2025.06.023_bb0120","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/CAD.0000000000001701","article-title":"Low-dose anlotinib plus immune checkpoint inhibitors offers better efficacy and safety in advanced non-small cell lung cancer treatment","volume":"36","author":"Tan","year":"2025","journal-title":"Anti-Cancer Drugs"},{"issue":"3","key":"10.1016\/j.ygyno.2025.06.023_bb0125","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/S1470-2045(24)00648-X","article-title":"Dose optimisation to improve access to effective cancer medicines","volume":"26","author":"Tannock","year":"2025","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.06.023_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7024","article-title":"A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative","volume":"13","author":"Li","year":"2024","journal-title":"Cancer Med."},{"issue":"15","key":"10.1016\/j.ygyno.2025.06.023_bb0135","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/1759-7714.15310","article-title":"Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: a network meta-analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Thorac. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2025.06.023_bb0140","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.clon.2022.02.015","article-title":"Platinum-based chemotherapy \u2018rechallenge\u2019 in advanced non-ovarian solid malignancies","volume":"34","author":"Hack","year":"2022","journal-title":"Clin. Oncol. (R Coll Radiol)"},{"issue":"18","key":"10.1016\/j.ygyno.2025.06.023_bb0145","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1002\/cncr.30830","article-title":"Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: myth or reality?","volume":"123","author":"Tomao","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2025.06.023_bb0150","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1007\/s11033-019-04794-8","article-title":"Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis","volume":"46","author":"Mansha","year":"2019","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.ygyno.2025.06.023_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007929","article-title":"Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from study 111\/KEYNOTE-146","volume":"12","author":"Makker","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2025.06.023_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007366","article-title":"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"17","key":"10.1016\/j.ygyno.2025.06.023_bb0165","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1158\/1078-0432.CCR-23-3417","article-title":"Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers","volume":"30","author":"French","year":"2024","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:21:18Z","timestamp":1777018878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825008996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":33,"alternative-id":["S0090825825008996"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.06.023","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose lenvatinib plus toripalimab for patients with platinum-resistant recurrent ovarian cancer: preliminary results from a multicenter, phase II trial (NCT06241105)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}